Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/11208
Tipo
ArtículoDerechos de autor
Acceso restringido
Colecciones
- INI - Artigos de Periódicos [3460]
Metadatos
Mostrar el registro completo del ítem
RISK OF REACTIVATION OF TOXOPLASMIC RETINITIS FOLLOWING INTRAOCULAR PROCEDURES WITHOUT THE USE OF PROPHYLACTIC THERAPY
Autor
Afiliación
Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.
Moorfields Eye Hospital. London, UK.
Moorfields Eye Hospital. London, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil
Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.
Moorfields Eye Hospital. London, UK.
Moorfields Eye Hospital. London, UK.
Moorfields Eye Hospital. London, UK.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil
Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.
Moorfields Eye Hospital. London, UK.
Resumen en ingles
BACKGROUND/AIMS: Toxoplasmic retinochoroiditis is the commonest known cause of posterior uveitis worldwide and reactivation is unpredictable. Based on results from one study, the authors proposed that antitoxoplasmic therapy should be initiated as prophylaxis for intraocular surgery in patients with toxoplasmic scars. The aim of this study is to analyse the risk of toxoplasmic retinochoroiditis reactivation following intraocular procedures. METHODS: Retrospective analysis of the medical records of a total of 69 patients who underwent intraocular surgery and presented with toxoplasmic retinochoroiditis scars. RESULTS: No patient received prophylactic antitoxoplasmic therapy. Reactivation following the surgical procedure occurred in four cases, with one at 3 months and the others respectively at 13, 14 and 17 months.
CONCLUSIONS:
Our study shows that intraocular surgery did not result in a significant reactivation rate of toxoplasmic retinochoroiditis in the absence of preoperative prophylactic antitoxoplasmic therapy.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Compartir